The prevalence of major depressive disorder (MDD) is \~5.0%, and rates of co-occurring SUDs in these patients approach 40-50%. Specifically, rates of co-morbid cannabis use disorder (CUD) in patients with MDD are elevated 2-3 fold compared to 2.9% in the general population, and is associated with poorer treatment outcomes and impaired cognitive and psychosocial functioning in comparison to MDD patients without CUD. Most studies of cannabis use in MDD are cross-sectional in design, and therefore causal relationships are unclear. This study investigates the effects of cannabis abstinence over a 28-day period in patients with MDD with co-occurring CUD using a randomized controlled design, namely contingent reinforcement.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Changes in Depressive Symptomology from Baseline to Week 4
Timeframe: [Time Frame: Weekly (Day 0, Day 7, Day 14, Day 21, Day 28)]
Changes in Anxious Symptomology from Baseline to Week 4
Timeframe: [Time Frame: Weekly (Day 0, Day 7, Day 14, Day 21, Day 28)]
Changes in Sleep Symptomology from Baseline to Week 4
Timeframe: [Time Frame: Weekly (Day 0, Day 7, Day 14, Day 21, Day 28)]
Changes in Anhedonia from Baseline to Week 4
Timeframe: [Time Frame: Weekly (Day 0, Day 7, Day 14, Day 21, Day 28)]